Sector News

After a round trip, ex-Intellia CEO Bermingham lands back at Atlas

February 6, 2018
Life sciences

A couple of months ago, Intellia’s leader and founder Nessan Bermingham, Ph.D., left the CRISPR company, but we knew not where.

Today, we found out, and there is little surprise on this occasion as Bermingham has returned full circle, back at Atlas Ventures, the firm that also helped launch Intellia, one of a handful of U.S. biotechs hoping to make good on the early promise of CRISPR gene editing. He first started at the VC firm back in 2002.

Nessan will now be involved “with the formation and leadership of ground-breaking new biotechnology companies as part of the Atlas platform,” the firm said in a brief statement.

“I am thrilled to be working with Atlas again as we translate cutting-edge scientific advances into medicines for patients in need and build great companies,” says Bermingham.

Bermingham co-founded Intellia with Atlas back in 2014, leading the company from its seed investment and incubation at Atlas through to its $108 million IPO.

He first joined Atlas in 2002 and worked on multiple Atlas portfolio companies across various stages

“Nessan is a relentless entrepreneur and operator who has proven his ability to build breakthrough biotech companies from the ground up,” said Jean François Formela, partner at Atlas.

“We are excited to welcome him back to Atlas and look forward to creating transformational new companies with him.”

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach